GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (NAS:GH) » Definitions » Return-on-Tangible-Asset

Guardant Health (Guardant Health) Return-on-Tangible-Asset

: -42.05% (As of Dec. 2023)
View and export this data going back to 2018. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Guardant Health's annualized Net Income for the quarter that ended in Dec. 2023 was $-748.2 Mil. Guardant Health's average total tangible assets for the quarter that ended in Dec. 2023 was $1,779.2 Mil. Therefore, Guardant Health's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -42.05%.

The historical rank and industry rank for Guardant Health's Return-on-Tangible-Asset or its related term are showing as below:

GH' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -39.58   Med: -23.54   Max: -9.93
Current: -28.28

During the past 8 years, Guardant Health's highest Return-on-Tangible-Asset was -9.93%. The lowest was -39.58%. And the median was -23.54%.

GH's Return-on-Tangible-Asset is ranked worse than
62.61% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: -8.34 vs GH: -28.28

Guardant Health Return-on-Tangible-Asset Historical Data

The historical data trend for Guardant Health's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => -9.93 [4] => -15.88 [5] => -18.28 [6] => -34.62 [7] => -28.46 )
Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Premium Member Only Premium Member Only Premium Member Only -9.93 -15.88 -18.28 -34.62 -28.46

Guardant Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.12 -34.55 -17.52 -19.08 -42.05

Competitive Comparison

For the Diagnostics & Research subindustry, Guardant Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health Return-on-Tangible-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Guardant Health's Return-on-Tangible-Asset falls into.



Guardant Health Return-on-Tangible-Asset Calculation

Guardant Health's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-479.449/( (1594.968+1774.152)/ 2 )
=-479.449/1684.56
=-28.46 %

Guardant Health's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-748.172/( (1784.271+1774.152)/ 2 )
=-748.172/1779.2115
=-42.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Guardant Health  (NAS:GH) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Guardant Health Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Guardant Health's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health (Guardant Health) Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Executives
Meghan V. Joyce director THE BOSTON BEER COMPANY, INC., ONE DESIGN CENTER PL., STE. 850, BOSTON MA 02210
Kumud Kalia officer: Chief Information Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Ines Dahne-steuber officer: Chief Operating Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Darya Chudova officer: Chief Technology Officer 3100 HANOVER STREET, PALO ALTO CA 94304
Helmy Eltoukhy director, officer: Chief Executive Officer 2 BARRY LANE, ATHERTON CA 94027
Amirali Talasaz director, officer: Chairman, President and COO 18 ISABELLA AVENUE, ATHERTON CA 94027
Musa Tariq director 3100 HANOVER STREET, PALO ALTO CA 94304
Amelia Merrill officer: SVP, People 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Stanley J Meresman director 2071 HUNTINGTON LANE, LOS ALTOS CA 94024
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Chris Freeman officer: Chief Commercial Officer 505 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Bahija Jallal director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Vijaya Gadde director C/O TWITTER INC, 1355 MARKET STREET SUITE 900, SAN FRANCISCO CA 94103